Immunotherapy Drugs Market Size, Share, and Trends 2026 to 2035

Revenue, 2025

USD 318.83 Bn

Forecast Year, 2035

USD 1,607.94 Bn

CAGR, 2026 - 2035

17.56%

Report Coverage

Global

What is the Immunotherapy Drugs Market Size?

The global immunotherapy drugs market size was estimated at USD 318.83 billion in 2025 and is predicted to increase from USD 376.22 billion in 2026 to approximately USD 1,607.94 billion by 2035, expanding at a CAGR of 17.56% from 2026 to 2035.

Immunotherapy Drugs Market Key Takeaway

• North America dominated the global market with the largest market share of 46% in 2025.
• By indication type, the cancer segment held the highest market share of 92% in 2025.
• By drug type, the monoclonal antibodies segment captured the biggest market share of 77% in 2025.

Immunotherapy Drugs Market Growth Factors

The rising prevalence of chronic diseases, rising healthcare expenditure, and growing adoption of the targeted therapy among the population are the major factors that propels the growth of the global immunotherapy drugs market. The growing popularity of the biosimilars owing to the approvals received by certain biosimilar drugs from the authorities like FDA and EMA is expected to be an important driving factor in the forthcoming years. The growing investments in the research and development by the biotechnology and pharmaceutical companies, rising number of research labs, and growing research collaborations by the key market players are the several crucial factors that are expected to have a significant impact on the market growth during the forecast period. The rapidly growing biopharmaceutical industry owing to the rising government support and rising corporate investments will augment the growth of the immunotherapy drugs market. Furthermore, the rising awareness regarding the benefits of the immunotherapy drugs over the traditional treatment procedures is significantly spurring the demand for the immunotherapy drugs.

Traditional therapies were expensive and were inefficient in treating the diseases. For instance, the chemotherapy used for the treatment of cancer, was very toxic. It involved the risks of organ failure, reoccurrence of cancer, and various other side-effects, which may cost the life of the patient even after receiving the treatment. The immunotherapy has low side-effects can are free from the risks that were associated with the traditional chemotherapy. This has significantly driven the demand for the immunotherapy drugs across the globe.

Market Scope

Segment Insights

Drug Type Insights

The monoclonal antibodies segment dominated the global immunotherapy market in 2025. The monoclonal antibodies are considered to be the most effective type of immunotherapy that cures various chronic diseases. The higher safety of the immunotherapy owing to the lower toxicity results in minimal or no side effects. The increasing popularity of the monoclonal antibodies due to its low side-effects is fueling the demand for the monoclonal antibodies. The government authorities like FDA and EMA are playing a crucial role in the rising adoption of the monoclonal antibodies. In 2017, the FDA and EMA collectively approved 73 monoclonal antibodies.

The vaccines segment is estimated to be the fastest-growing segment during the forecast period. The rising burden of various infections and diseases is fueling the investments on the development of vaccines. For instance, in 2020, the rapid spread of the COVID-19 disease have positively impacted the growth of this segment as the top pharmaceutical companies were engaged in the development of immunotherapy-based vaccines and drugs.

Therapeutic Area Insights

Cancer was the most dominant therapeutic area in 2025. This is attributed to the increased prevalence of cancer across the globe. As per the GLOBOCAN, a report published by the International Agency for Research on Cancer, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe, in 2020. The new cancer cases are expected to rise by 47% from 2020 to 2040, globally. Therefore, it is estimated that around 28.4 million new cancer cases will be recorded in 2040 across the globe. The most prominent type of cancer includes lungs cancer, prostate cancer, breast cancer, and colorectal cancer. The increased demand for the immunotherapy drugs to treat cancer has fostered the growth of this segment and the rapidly growing cases of cancer are anticipated to sustain the dominance of this segment throughout the forecast period. Moreover, the immunotherapy drugs targets the cancer cells in the body and treats I without harming the normal cells, which leads to low or no side-effects. These advantages of the new immunotherapy drugs over the traditional chemotherapy are compelling the patients to adopt the immunotherapy drugs that foster the growth of this segment, globally.

Regional Insights

U.S. Immunotherapy Drugs Market Size and Growth 2026 to 2035

The U.S. immunotherapy drugs market size accounted for USD 102.66 billion in 2025 and is expected to be worth around USD 528.75 billion by 2035, growing at a CAGR of 17.81% from 2026 to 2035.

North America dominated the global immunotherapy market in 2025. This can be attributed to the increased prevalence of the chronic diseases in the major market like US. Around half of the US population is suffering from one or more chronic diseases. This has resulted in the increased healthcare expenditure. Moreover, as per the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. The colorectal cancer, lungs cancer, prostate cancer, and breast cancer are the most prominent types of cancers in US. The increased awareness among the US population regarding the immunotherapy drugs coupled with the increased healthcare expenditure and enhanced access to the healthcare facilities has augmented the market growth in this region. The presence of developed healthcare infrastructure and presence of several top biopharmaceutical companies has significantly contributed towards the market growth.

U.S. Market Trends

The use of AI in the discovery of biomarkers and patient selection for improved efficacy of immunotherapeutic is quickly becoming a reality in the U.S. landscape. CAR-Ts are being produced as they are becoming more widely available. The focus of regulatory authorities is also shifting to optimisation of the doses of these immune checkpoint blocking drugs, and the country's robust healthcare system continues to be a driver of the highest uptake of immunotherapy drugs.

Asia Pacific is estimated to be the most opportunistic market during the forecast period owing to the rising prevalence of target diseases among the population. According to the International Journal of General Medicine 2018, the mortality from the chronic diseases is rapidly rising in the low and middle income countries, accounting for around 75% of the global deaths from the chronic diseases. The alarming rise in the number of chronic diseases and deaths due to it is expected to spur the demand for the immunotherapy drugs in this region. Moreover, the rising government expenditure on the development of healthcare infrastructure and improving the access to the healthcare facilities is significantly fostering the growth of the immunotherapy drugs market in Asia Pacific.

China Market Trends

Cancer rates are rising in China, and health care has become increasingly upgraded, with a rapid rise in the use of immunotherapy drugs. The research effort and clinical trials are sufficient in the country to study tumour immunology. The demand for monoclonal antibodies and next-generation therapy is growing, and with it, there is growing interest in the biotechnology industry for studies on oncolytic virus immunotherapy.

What Are the Driving Factors of The Immunotherapy Drugs Market in Europe?

Europe is expected to grow at a significant CAGR during the forecast period. The European market is a proven one for immunotherapy products and also has a significant cancer burden with high regulatory activity to facilitate the uptake of biosimilars. Technological advances in treatment and good reimbursement policies, combined with the use of these therapies in specialist cancer treatment centers, are also contributing to an increasing use of these treatments in major European countries.

Germany Market Trends

Companies such as BioNTech SE and Merck KGaA are making big investments in the development of cell-based immunotherapy to improve Germany's position in the market. The administration of drugs is also transitioning to drugs that are injected under the skin, enabling the drugs to reach the market quickly. The reimbursement support and the growing demand for oncology have kept PD-1 and PD-L1 inhibitors strong.

What Are the Driving Factors of The Immunotherapy Drugs Market in Latin America?

Latin America is expected to grow at a significant CAGR during the forecast period. The growing consciousness and the growing patient population in the Latin America (LA) region for targeted immunotherapy are the driving forces of the market. The growing awareness and the increasing number of patients available for targeted immunotherapy treatment in the Latin America region are driving the market.

Brazil Market Trends

With the emergence of new therapies in the form of immunotherapies, the use of monoclonal antibodies has become more and more popular in Brazil. Chronic diseases and cancers are increasing, and so is the need for state-of-the-art cancer treatments. Further, access to innovative immunotherapy drugs and cancer treatment services is being supported by collaborative efforts through strategic partnerships, outsourcing, and investment in the healthcare sector.

Immunotherapy Drugs Market Companies

• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc.
• AbbVie, Inc.
• Amgen, Inc.
• Merck & Co., Inc.
• Alligator Bioscience
• UbiVac
• Bristol-Myers Squibb
• Novartis International AG
• AstraZeneca plc

Recent Developments

• In January 2026, Zydus Lifesciences launched the world's first nivolumab biosimilar, Tishtha, in India at nearly a fourth of the price of BMS's Opdivo, significantly enhancing access to important cancer immunotherapy on January 22. (Source: https://www.moneycontrol.com)
• In August 2025, Intas Pharmaceuticals introduced HETRONIFLY™ (Serplulimab), the first globally approved PD-1 inhibitor for Extensive-Stage Small Cell Lung Cancer in India, following a European launch and a licensing agreement with Shanghai Henlius Biotech. (Source: https://www.prnewswire.com)
• In July 2019, Allergan Plc and Amgen, Inc. KANJINTITM, a biosimilar to Herceptin, and MVASi, a biosimilar to Avastin in the US. MVASI was the first cancer biosimilar that got the FDA approval.
• In May 2020, VinsBioproducts Ltd. collaborated with the University of Hyderabad and the CSIR Center for Cellular and Molecular Biology, in India to develop immunotherapy treatment for COVID-19.
• The various developmental strategies like partnerships, acquisitions, mergers, collaborations, and new product launches with latest and innovative features fosters market growth and offers lucrative growth opportunities to the market players.

Market Segmentation

By Drug Type

• Monoclonal Antibodies
• Vaccines
• Interleukins
• Interferons Alpha & Beta
• Others

By Therapeutic Area

• Cancer
• Infectious Diseases
• Autoimmune & Inflammatory Diseases
• Others

By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• MEA
• Rest of the World